Challenges for biosimilar sustainability in Europe

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Challenges for biosimilar sustainability in Europe

Home/Reports | Posted 10/05/2019 0 Post your comment

At the 17th Biosimilar Medicines Conference, Executive Director of the IQVIA Institute for Human Data Science (formerly the IMS Institute), Murray Aitken, outlined the challenges facing biosimilars in terms of long-term sustainability in Europe.

He explained how maintaining healthy competition among both makers of biosimilars and originator biologicals is essential to the long-term sustainability of biosimilars markets in Europe. He also believed in the importance of the contribution of biosimilars to sustainable healthcare systems in the region.

However, this sustainability is not yet assured. According to Aitken, expanding patient access to biologicals and maintaining prescriber control over treatment decisions are central to ensuring long-term improvements in patient care and outcomes.

Just one challenge for biosimilars is that advances in innovative medicines by makers of originator biologicals are bringing next-generation treatment options to providers and patients, potentially leaving a smaller volume of prior-generation use. In addition, fewer new blockbuster biologicals will become available for biosimilars competition over the next five years compared to in the last five years. This will require biosimilars makers to have a long-term perspective.

Another challenge is that large variability still exists across countries in the contribution biosimilars are making to the sustainability of hospital and non-hospital budgets, and this presents significant opportunities for improvement.
In the following series of three articles the biosimilars share in Europe and new biosimilar opportunities, the level of biosimilars competition in different countries, and contributary factors to long-term sustainability of the biosimilars market in Europe are discussed in more detail.

Conflict of interest
The author of the presentation [1] did not provide any conflict of interest statement.

The level of biosimilars competition in Europe varies

Reference
1. Aitken M. Advancing Long-term Biosimilar Sustainability in Europe: The Challenges Ahead. Medicines for Europe 17th Biosimilar Medicines Conference; 28-29 March 2019; Amsterdam, The Netherlands.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.